Salvage Chemotherapy for Refractory Transitional Cell Carcinoma of the Ovary (TCC)

By Sweeten K.M.   Gershenson D.M.   Burke T.W.   Morris M.   Levenback C.   Silva E.G.  

Gynecologic Oncology, Vol. 59, Iss. 2, 1995-11 ,pp. : 211-215

Academic Press

Access to resources Recommend Favorite

Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III Disease

By Goff B.A.   Sainz de la Cuesta R.   Muntz H.G.   Fleischhacker D.   Ek M.   Rice L.W.   Nikrui N.   Tamimi H.K.   Cain J.M.   Greer B.E.   Fuller Jr A.F.  

Gynecologic Oncology, Vol. 60, Iss. 3, 1996-03 ,pp. : 412-417

Academic Press

Access to resources Recommend Favorite

Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary (Review)

By      

Oncology Letters, Vol. 10, Iss. 2, 2015-01 ,pp. : 571-576

Spandidos Publications

Access to resources Recommend Favorite

Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma

By                

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 1017-1022

Spandidos Publications

Access to resources Recommend Favorite

Differential response to transforming growth factor (TGF)- and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types

By Ramp U.   Reinecke P.   Gabbert H.E.   Gerharz C.-D.  

European Journal of Cancer, Vol. 36, Iss. 7, 2000-05 ,pp. : 932-941

Elsevier

Access to resources Recommend Favorite